Takeda Extends Long-Term Stock Incentive Plans for Directors and Management into 2026

The latest update is out from Takeda Pharmaceutical Co ( (JP:4502) ).

Takeda’s board has approved the continuation in 2026 of its stock compensation plan for directors and the stock grant system for Japan-based company management, both designed as long-term incentive schemes. The framework distinguishes between executive directors, external directors and audit committee members, tailoring the balance of performance-linked and non-performance-linked equity awards to their roles.

Under the refreshed structure, internal directors not on the Audit and Supervisory Committee receive a mix of performance share units and restricted stock units, with payouts tied to three-year targets such as revenue, profit and R&D metrics, followed by mandatory holding periods to reinforce long-term alignment. External directors and audit committee members receive only restricted stock units linked to share price, with oversight and performance evaluations handled by a compensation committee composed entirely of external directors to reinforce transparency and governance.

The most recent analyst rating on (JP:4502) stock is a Buy with a Yen6900.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

More about Takeda Pharmaceutical Co

Takeda Pharmaceutical Co., headquartered in Osaka and Cambridge, is a global biopharmaceutical company focused on developing and commercializing innovative medicines. The group operates across key therapeutic areas and uses equity-based compensation to align management and directors with long-term corporate value and shareholder interests.

Average Trading Volume: 4,500,142

Technical Sentiment Signal: Buy

Current Market Cap: Yen8192.4B

See more data about 4502 stock on TipRanks’ Stock Analysis page.